Deoxyschizandrin Inhibits PTEN to Regulate Inflammation in Doxorubicin-induced Hepatotoxicity
Jinhai Wang1★, Naijing Zhou2★ Corresponding author
- 1Department of Emergency, Affiliated Changzhou Municipal No. 2 People’s Hospital, Nanjing Medical University, Changzhou, PEOPLE’S REPUBLIC OF CHINA.
- 2Department of Critical Care Medicine, Affiliated Changzhou Municipal No. 2 People’s Hospital, Nanjing Medical University, Changzhou, PEOPLE’S REPUBLIC OF CHINA.
CORRESPONDENCE
Jinhai Wang
Naijing Zhou,Department of Critical Care Medicine, Affiliated Changzhou Municipal No. 2 People’s Hospital, Nanjing Medical University, Changzhou, PEOPLE’S REPUBLIC OF CHINA.
Volume 19, Issue 2 · pp. 439–447 · PUBLISHED 2023 · DOI: 10.1177/09731296231165593
ABSTRACT
Aim: Doxorubicin (DOX) has long been criticized for its cardiotoxicity, yet one cannot overlook its hepatotoxicity. Deoxyschizandrin (Deo) is a type of monomer used in traditional Chinese medicine that has a powerful anti-inflammatory action and is frequently used to treat a variety of inflammatory diseases. However, its therapeutic effect on DOX-induced hepatotoxic inflammatory reactions is still unknown. Materials and Methods: In this study, DOX was used to induce hepatotoxicity in rats, and the effects of Deo on hepatotoxicity and hepatic inflammation were investigated. Results: The results show that Deo protects liver function by inhibiting PETN, which regulates DOX-induced liver inflammation. Conclusion: The anti-inflammatory effect of Deo in DOX-induced hepatotoxicity is attributed to the inhibition of phosphatase and tensin homolog deleted on chromosome ten (PTEN) and the increase in AKT phosphorylation.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Wang, J., & Zhou, N. (2023). Deoxyschizandrin Inhibits PTEN to Regulate Inflammation in Doxorubicin-induced Hepatotoxicity. Pharmacognosy Magazine, 19(2), 439–447. https://doi.org/10.1177/09731296231165593